1. Home
  2. PACK vs CAPR Comparison

PACK vs CAPR Comparison

Compare PACK & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PACK
  • CAPR
  • Stock Information
  • Founded
  • PACK 1972
  • CAPR 2005
  • Country
  • PACK United States
  • CAPR United States
  • Employees
  • PACK N/A
  • CAPR N/A
  • Industry
  • PACK Containers/Packaging
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PACK Consumer Discretionary
  • CAPR Health Care
  • Exchange
  • PACK Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • PACK 313.3M
  • CAPR 324.6M
  • IPO Year
  • PACK N/A
  • CAPR N/A
  • Fundamental
  • Price
  • PACK $5.29
  • CAPR $6.28
  • Analyst Decision
  • PACK Buy
  • CAPR Strong Buy
  • Analyst Count
  • PACK 3
  • CAPR 8
  • Target Price
  • PACK $7.17
  • CAPR $24.75
  • AVG Volume (30 Days)
  • PACK 1.3M
  • CAPR 1.4M
  • Earning Date
  • PACK 08-05-2025
  • CAPR 08-11-2025
  • Dividend Yield
  • PACK N/A
  • CAPR N/A
  • EPS Growth
  • PACK N/A
  • CAPR N/A
  • EPS
  • PACK N/A
  • CAPR N/A
  • Revenue
  • PACK $380,700,000.00
  • CAPR $13,392,150.00
  • Revenue This Year
  • PACK $10.14
  • CAPR N/A
  • Revenue Next Year
  • PACK $7.92
  • CAPR $6,061.53
  • P/E Ratio
  • PACK N/A
  • CAPR N/A
  • Revenue Growth
  • PACK 10.38
  • CAPR N/A
  • 52 Week Low
  • PACK $2.91
  • CAPR $3.98
  • 52 Week High
  • PACK $8.70
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • PACK 67.12
  • CAPR 36.33
  • Support Level
  • PACK $5.02
  • CAPR $6.17
  • Resistance Level
  • PACK $6.31
  • CAPR $7.30
  • Average True Range (ATR)
  • PACK 0.33
  • CAPR 0.43
  • MACD
  • PACK 0.10
  • CAPR -0.11
  • Stochastic Oscillator
  • PACK 55.24
  • CAPR 4.53

About PACK Ranpak Holdings Corp

Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. Geographically, it derives a majority of its revenue from Europe/Asia. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: